SG11202112856QA - Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer - Google Patents
Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancerInfo
- Publication number
- SG11202112856QA SG11202112856QA SG11202112856QA SG11202112856QA SG11202112856QA SG 11202112856Q A SG11202112856Q A SG 11202112856QA SG 11202112856Q A SG11202112856Q A SG 11202112856QA SG 11202112856Q A SG11202112856Q A SG 11202112856QA SG 11202112856Q A SG11202112856Q A SG 11202112856QA
- Authority
- SG
- Singapore
- Prior art keywords
- naphthoquinone
- complexes
- cancer
- treatment
- functionalized gold
- Prior art date
Links
- ZRKYGJAXMUMYJX-UHFFFAOYSA-N C=C1C(C2=CC=CC=C2C(C1)=O)=O.[Au] Chemical class C=C1C(C2=CC=CC=C2C(C1)=O)=O.[Au] ZRKYGJAXMUMYJX-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/12—Gold compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/10—Silver compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851187P | 2019-05-22 | 2019-05-22 | |
| PCT/US2020/034415 WO2020237225A1 (en) | 2019-05-22 | 2020-05-22 | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112856QA true SG11202112856QA (en) | 2021-12-30 |
Family
ID=73459479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112856QA SG11202112856QA (en) | 2019-05-22 | 2020-05-22 | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220340601A1 (en) |
| EP (1) | EP3972981A4 (en) |
| JP (1) | JP2022532801A (en) |
| KR (1) | KR20220024123A (en) |
| CN (1) | CN114174305A (en) |
| AU (1) | AU2020279478A1 (en) |
| CA (1) | CA3140716A1 (en) |
| IL (1) | IL288176A (en) |
| MX (1) | MX2021014195A (en) |
| SG (1) | SG11202112856QA (en) |
| WO (1) | WO2020237225A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003483D0 (en) * | 2010-03-02 | 2010-04-14 | Univ St Andrews | Gold complexes |
| US8900654B2 (en) * | 2011-07-29 | 2014-12-02 | Thin Film Electronics, Inc. | Methods of polymerizing silanes and cyclosilanes using N-heterocyclic carbenes, metal complexes having N-heterocyclic carbene ligands, and lanthanide compounds |
| CA2864420C (en) * | 2012-02-13 | 2016-11-15 | Naidu S. Chowdari | Enediyne compounds, conjugates thereof, and uses and methods therefor |
| WO2019006327A1 (en) * | 2017-06-30 | 2019-01-03 | Board Of Regents, The University Of Texas System | Naphthoquinone containing gold carbene complexes and methods of uses thereof |
-
2020
- 2020-05-22 JP JP2021569297A patent/JP2022532801A/en active Pending
- 2020-05-22 KR KR1020217041752A patent/KR20220024123A/en unknown
- 2020-05-22 CA CA3140716A patent/CA3140716A1/en active Pending
- 2020-05-22 EP EP20809519.0A patent/EP3972981A4/en active Pending
- 2020-05-22 AU AU2020279478A patent/AU2020279478A1/en active Pending
- 2020-05-22 CN CN202080050300.4A patent/CN114174305A/en active Pending
- 2020-05-22 WO PCT/US2020/034415 patent/WO2020237225A1/en unknown
- 2020-05-22 MX MX2021014195A patent/MX2021014195A/en unknown
- 2020-05-22 SG SG11202112856QA patent/SG11202112856QA/en unknown
- 2020-05-22 US US17/595,670 patent/US20220340601A1/en active Pending
-
2021
- 2021-11-16 IL IL288176A patent/IL288176A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL288176A (en) | 2022-01-01 |
| EP3972981A1 (en) | 2022-03-30 |
| AU2020279478A1 (en) | 2021-12-09 |
| KR20220024123A (en) | 2022-03-03 |
| EP3972981A4 (en) | 2023-05-24 |
| US20220340601A1 (en) | 2022-10-27 |
| WO2020237225A1 (en) | 2020-11-26 |
| CN114174305A (en) | 2022-03-11 |
| CA3140716A1 (en) | 2020-11-26 |
| MX2021014195A (en) | 2022-02-21 |
| JP2022532801A (en) | 2022-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266245B (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| IL264598A (en) | Modified antibody-albumin nanoparticle complexes for cancer treatment | |
| IL280510A (en) | Antibody-drug conjugates for use in the treatment of metastatic brain tumor | |
| HK1248589A1 (en) | Use of ferric citrate in the treatment of iron-deficiency anemia | |
| IL277421B (en) | Flagellin polypeptide from the genus enterococcus for use in treating cancer | |
| IL290415A (en) | Deuterated compounds for use in the treatment of cancer | |
| IL277173A (en) | A dbait molecule against acquired resistance in the treatment of cancer | |
| EP3781180A4 (en) | Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer | |
| ZA201209452B (en) | Gold complexes for use in the treatment of cancer | |
| IL288176A (en) | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer | |
| SG11202007005UA (en) | Use of crassocephalum rabens extract in the treatment of breast cancer | |
| ZA202106015B (en) | 2-hydroxypropyl-β-cyclodextrin (hpβcd) for use in the treatment of breast cancer | |
| EP4101471A4 (en) | Nanoparticles for cancer treatment | |
| PL3820609T3 (en) | Use of n-chelating ruthenium complexes in the metathesis reaction | |
| WO2020033663A3 (en) | Binding molecules to tumor associated macrophages and methods of use | |
| SG11202100571TA (en) | Anti-lypd3 car t-cell therapy for the treatment of cancer | |
| IL271703B (en) | Use of macroazapyridinophanes metal complexes in the treatment of diseases | |
| GB201913467D0 (en) | Improved cytotoxic therapy to treat cancer in the cns | |
| GB201907204D0 (en) | Cancer treatment 3 | |
| GB201907150D0 (en) | Cancer treatment 2 | |
| IL281782A (en) | Pharmaceutical combination for the treatment of cancer | |
| IL273054B1 (en) | Abx196 for use in the treatment of bladder cancer | |
| RS62937B1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |